相似文献
1
Altering the intratumoral localization of macrophages to inhibit cancer progression.
Oncoimmunology. 2014 Jan 1;3(1):e27872. doi: 10.4161/onci.27872. Epub 2014 Feb 14.
2
Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.
Cancer Cell. 2013 Dec 9;24(6):695-709. doi: 10.1016/j.ccr.2013.11.007.
3
Location, location, location: macrophage positioning within tumors determines pro- or antitumor activity.
Cancer Cell. 2013 Dec 9;24(6):687-9. doi: 10.1016/j.ccr.2013.11.014.
4
A complementary peptide approach applied to the design of novel semaphorin/neuropilin antagonists.
J Neurochem. 2005 Mar;92(5):1180-90. doi: 10.1111/j.1471-4159.2004.02950.x.
5
Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis.
Oncogene. 2015 Mar 19;34(12):1584-95. doi: 10.1038/onc.2014.79. Epub 2014 Apr 14.
6
Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2.
Cell Adh Migr. 2011 May-Jun;5(3):266-75. doi: 10.4161/cam.5.3.16294. Epub 2011 May 1.
7
Semaphorin 3A gets involved in the establishment of mouse tooth eruptive pathway.
J Mol Histol. 2019 Oct;50(5):427-434. doi: 10.1007/s10735-019-09838-8. Epub 2019 Jul 3.
8
The role of the hypoxia-Nrp-1 axis in the activation of M2-like tumor-associated macrophages in the tumor microenvironment of cervical cancer.
Mol Carcinog. 2019 Mar;58(3):388-397. doi: 10.1002/mc.22936. Epub 2018 Nov 18.
9
Semaphorin 3F Serves as a Tumor Suppressor in Esophageal Squamous Cell Carcinoma and is Associated With Lymph Node Metastasis in Disease Progression.
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820928117. doi: 10.1177/1533033820928117.
10
Overexpression of semaphorin 3A promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma after curative resection.
Oncotarget. 2016 Aug 9;7(32):51733-51746. doi: 10.18632/oncotarget.10104.
引用本文的文献
1
The strange Microenvironment of Glioblastoma.
Rev Neurol (Paris). 2023 Jun;179(5):490-501. doi: 10.1016/j.neurol.2023.03.007. Epub 2023 Mar 22.
2
Semaphorins as Potential Immune Therapeutic Targets for Cancer.
Front Oncol. 2022 Jan 27;12:793805. doi: 10.3389/fonc.2022.793805. eCollection 2022.
3
ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosis.
Cell Mol Life Sci. 2022 Jan 20;79(2):83. doi: 10.1007/s00018-021-04124-x.
4
SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia.
J Exp Clin Cancer Res. 2021 Apr 15;40(1):131. doi: 10.1186/s13046-021-01929-3.
5
Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis.
Annu Rev Physiol. 2019 Feb 10;81:535-560. doi: 10.1146/annurev-physiol-020518-114721.
6
Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
EMBO Mol Med. 2017 Dec;9(12):1629-1645. doi: 10.15252/emmm.201607445.
7
The role of the semaphorins in cancer.
Cell Adh Migr. 2016 Nov;10(6):652-674. doi: 10.1080/19336918.2016.1197478. Epub 2016 Aug 17.
8
Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.
J Control Release. 2015 Dec 10;219:192-204. doi: 10.1016/j.jconrel.2015.08.017. Epub 2015 Aug 12.
本文引用的文献
1
Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.
Cancer Cell. 2013 Dec 9;24(6):695-709. doi: 10.1016/j.ccr.2013.11.007.
2
Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population.
Cancer Res. 2014 Jan 1;74(1):24-30. doi: 10.1158/0008-5472.CAN-13-1196. Epub 2013 Nov 12.
3
Macrophage regulation of tumor responses to anticancer therapies.
Cancer Cell. 2013 Mar 18;23(3):277-86. doi: 10.1016/j.ccr.2013.02.013.
4
Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.
J Clin Invest. 2012 May;122(5):1832-48. doi: 10.1172/JCI58976. Epub 2012 Apr 9.
5
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
Nat Rev Clin Oncol. 2011 May 31;8(7):393-404. doi: 10.1038/nrclinonc.2011.83.
6
Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models.
Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):741-9. doi: 10.1161/ATVBAHA.110.211920. Epub 2011 Jan 4.
7
Structural basis for semaphorin signalling through the plexin receptor.
Nature. 2010 Oct 28;467(7319):1123-7. doi: 10.1038/nature09473. Epub 2010 Sep 29.
8
Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia.
Blood. 2009 Jul 23;114(4):844-59. doi: 10.1182/blood-2008-12-195941. Epub 2009 May 19.
9
Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function.
Blood. 2006 Apr 15;107(8):3321-9. doi: 10.1182/blood-2005-06-2445. Epub 2005 Dec 27.
10
Semaphorin 3A displays a punctate distribution on the surface of neuronal cells and interacts with proteoglycans in the extracellular matrix.
Mol Cell Neurosci. 2005 May;29(1):40-55. doi: 10.1016/j.mcn.2004.12.009.
Zotero 插件